IOncology

Gastrointestinal stromal tumors (GIST) are mesenchymal tumors driven by mutations in oncogenes. In recent years, various types of small-molecule tyrosine kinase inhibitors (TKIs) have provided new treatment options for patients with advanced GIST, but there remains a significant unmet need in clinical care. During the 2024 ESMO Annual Meeting, Dr. Jian Li's team from Peking University Cancer Hospital presented updated data from the follow-up treatment analysis of the INTRIGUE China bridging study on ripretinib, offering further insights into the clinical application of such novel drugs.

With the rapid development of genetic testing technology, the treatment strategies for patients with cancer of unknown primary (CUP) are undergoing revolutionary changes. During the 2024 ESMO Congress, the World CUP Alliance held a special "Roundtable on Access & Awareness of Precision Oncology" at the ESMO Congress, looking forward to the current treatment of CUP patients. After the meeting, Oncology Frontier specially invited Prof. Xichun Hu from Fudan University Shanghai Cancer Center, Prof. Linda Mileshkin from Peter MacCallum Cancer Center in Australia, Prof. Manel Esteller from Josep Carreras Leukemia Research Institute in Spain, and Prof. Qinghua Xu from Hangzhou Gene Help Technology Co., Ltd Help to gather together and discuss in depth the new advances in the treatment of CUP. From the positive data of the CUPISCO trial to the results of the Fudan CUP-001 study, the experts not only shared cutting-edge research results but also proposed valuable insights on how to improve the diagnostic accuracy for CUP patients and promote the implementation of personalized treatment plans, bringing new treatment hopes for CUP patients worldwide.

New data shows that breastfeeding does not increase the risk of breast cancer recurrence or developing secondary breast cancer, nor does it pose any health risks to the child.

With the rapid advancement of science and technology, there is growing hope that more cancers can be intercepted at their earliest stages. The European Society for Medical Oncology (ESMO) is deeply exploring the field of prevention to ensure that oncologists are educated and guided in this evolving area.

From September 13 to 17, the 2024 ESMO Annual Meeting is in full swing in Barcelona, Spain. Oncology Frontier is attending the event and bringing you first-hand insights from the conference. During the non-metastatic non-small cell lung cancer (NSCLC) paper session held on September 13, Dr. Suresh Senan from Amsterdam, Netherlands, presented the latest results from the ADRIATIC study, where subgroup analysis further supports previous practice-changing findings.

The European Society for Medical Oncology Congress 2024(ESMO 2024) opened on September 13, in Barcelona,Spain. Lung cancer remains one of the key areas of focus,with several groundbreaking studies presented at the conference. Oncology Frontier invited Dr.Yuankai Shi, principal investigator of the INSPIRE study from the Cancer Hospital Chinese Academy of Medical Sciences,to share the latest data from this year's ESMO conference and discuss the clinical value of the study in treating anaplastic lymphoma kinase(ALK)-positive advanced non-small cell lung cancer(NSCLC).

On July 2, 2024, the "ADC High-Level Closed-Door Seminar," chaired by Vice President Yong Yang of China Pharmaceutical University and President Jin Li of Shanghai Gaobo Oncology Hospital, was grandly held in Shanghai. The seminar explored the current status and future of ADC development. During the event, Oncology Frontier interviewed Professor Baohui Han from the Shanghai Chest Hospital . Combining recent ASCO conference updates, Professor Han analyzed the efficacy results and safety management points of ADC treatment in NSCLC and shared insights on the future prospects of ADC development.

The development of modern oncology has provided a variety of groundbreaking treatment options for lung cancer, making it one of the most rapidly evolving solid tumors. To help clinical physicians gain an in-depth and comprehensive understanding of the significant advancements in this field, "Oncology Frontier" has joined forces with Dr. Hua Zhong and Dr. Baohui Han, Director of the Department of Respiratory and Critical Care Medicine at Shanghai Jiao Tong University School of Medicine Affiliated Chest Hospital,  to create a clinical progress series called "Zhong's Insights, Hui's Wisdom." By interpreting high-quality clinical studies in the field of lung cancer, this series aims to promote the improvement of clinical diagnostic and treatment practices. In this 23rd issue of the “Zhong's Insights, Hui's Wisdom” series, Dr. Hua Zhong and Dr. Baohui Han provide their expert analysis on the relationship between PD-L1 expression levels and the efficacy of first-line crizotinib treatment in ROS-1 fusion-positive non-small cell lung cancer (NSCLC) patients. The study was published in Lung Cancer by the Department of Respiratory and Critical Care Medicine at Shanghai Jiao Tong University School of Medicine Affiliated Chest Hospital, with Dr. Runbo Zhong as the corresponding author.

The 2024 World Conference on Lung Cancer (WCLC) will be held in San Diego, USA, from September 7-10. Dr. Matthew Smeltzer, Associate Professor , Division of Epidemiology, Biostatistics, and Environmental Health at the University of Memphis, Tennessee, will present the analysis of the "2024 International Association for the Study of Lung Cancer (IASLC) Global Survey on Biomarker Testing" in an oral session titled "OA03 Predicting the Future: New Pathology Assessments and Imaging Biomarkers."

The 2024 World Conference on Lung Cancer (WCLC), hosted by the International Association for the Study of Lung Cancer (IASLC), is currently underway in San Diego, USA. Oncology Frontier has invited leading Chinese lung cancer experts to analyze the key research data from this conference. This article highlights Dr. Nan Bi from the Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, as she shares her thoughts on the LAURA study results (Abstract No. OA12.03).